Why GLP-1 medication alone isn't enough (and what to offer your employees instead)

Medications like Wegovy, Zepbound, and Ozempic have completely reshaped the landscape of obesity treatment. These GLP-1 receptor agonists are highly effective: they reduce appetite, regulate blood sugar, and lead to significant weight loss. Unsurprisingly, demand has surged across the U.S., with employers now facing mounting pressure to cover them.

But while these medications work — they're not magic.

Numerous studies have shown that behavior change and weight loss must go hand-in-hand. Medication alone rarely results in sustained success. When patients stop taking GLP-1s, most regain the weight within months if no lifestyle change has occurred (JAMA).

For self-funded employers, this isn't just a clinical concern — it's a financial one. Covering GLP-1s without a behavior change strategy can lead to:

• Long-term drug dependency
• High pharmacy costs
• Minimal ROI on obesity-related claims reduction
• Member dissatisfaction and churn when weight rebounds

What happens when GLP-1s are used alone

Medication-only models, often seen in direct-to-consumer platforms, may offer:

• Fast access to prescriptions
• Minimal clinical oversight
• No structured support or tapering strategy

The result? Short-term weight loss — followed by high rates of dropout, weight regain, and prolonged medication use. This is often referred to as the "GLP-1 trap": employees lose weight quickly, but the underlying behaviors don't change — so as soon as the medication stops, the weight comes back.

According to the American Journal of Managed Care (AJMC), up to 68% of GLP-1 users discontinue within 12 months. Yet many continue to incur costs due to re-initiation or ongoing treatment for obesity-related conditions like type 2 diabetes, hypertension, or sleep apnea.

From an employer's perspective, this means high spend with little long-term gain — and no visibility into success metrics.

The coaching-first difference: sustainable outcomes and lower cost

At Embla, we believe GLP-1s should be part of a broader care model — one rooted in behavior change.

That's why we lead with 1:1, high-quality coaching, supported by clinicians and driven by real human connection. Our coaching model is based on Acceptance & Commitment Therapy (ACT) — a science-backed approach used to change deep-seated patterns around eating, stress, and self-care.

Combined with clinical oversight and our lowest-effective-dose medication philosophy, this approach delivers:

• 16.7% average weight loss in 12 months, based on internal clinical outcomes
• 66% lower GLP-1 medication use, by starting low and escalating only if needed
• 8 in 10 members taper off medication without regaining weight, thanks to sustainable behavior change

These outcomes demonstrate that coaching-based weight loss programs are not only clinically effective but also financially responsible.

Why coaching is essential — not optional

GLP-1s suppress appetite — but they don't:

• Teach someone how to manage stress without turning to food
• Help them build healthy habits around movement, sleep, or meal planning
• Address body image, motivation, or emotional eating triggers
• Create long-term accountability after the medication ends

That's where coaching comes in. Embla coaches work with members to:

• Set achievable goals and build consistency in daily behaviors
• Identify and defuse unhelpful thoughts and food-related coping patterns
• Prepare for plateaus and relapses — and navigate through them
• Develop the confidence and skills to maintain weight loss for life

Real-world outcomes: what employers should expect

Employers implementing coaching-first models like Embla's can expect:

• Improved medication efficiency — members use lower doses and taper sooner, which reduces total drug spend
• Higher engagement and adherence — weekly video coaching drives strong retention and satisfaction
• Lower long-term costs — less reliance on high-cost GLP-1s, fewer comorbidities, and healthier employee populations
• Transparent reporting — dashboards that track individual and population-level outcomes, including weight loss, medication usage, and program ROI

We've worked with employers where 80–85% of members stay engaged for 6+ months, and more than half continue engaging after medication has ended — because they've built a trusted relationship with their coach.

Summary: a smarter model for sustainable weight loss

GLP-1s have changed the game — but they're just one tool.

Without behavior change, weight comes back. With coaching, members build the psychological skills and lifestyle foundations needed to lose weight — and keep it off.

If your organization is serious about offering obesity care that improves health and controls cost, it's time to think beyond the pill. Reach out to us to learn how Embla can help you offer more affordable and effective GLP-1 coverage.